6-Methyluracil derivatives as acetylcholinesterase inhibitors for treatment of Alzheimer's disease.
CONCLUSIONS: Experiments showed that the most potent AChE inhibitor compound 35 (6-methyluracil derivative) permeated the blood-brain barrier, improved working memory in the APP/PS1 transgenic mice and significantly reduced the number and area of Aβ plaques in the brain. Thus, compound 35 is a promising candidate as a bi-functional inhibitor of AChE for treatment of AD.
PMID: 26639718 [PubMed - in process]
Source: International Journal of Risk and Safety in Medicine - Category: Drugs & Pharmacology Tags: Int J Risk Saf Med Source Type: research
More News: Alzheimer's | Brain | Donepezil | Drugs & Pharmacology | Learning | Neurology | Statistics | Study | Toxicology | Universities & Medical Training